SAN FRANCISCO, June 7 /PRNewswire/ -- Nanodisc, Inc., a nano-bio convergence company commercializing nanotechnologies for drug discovery and delivery, announced that today at the BIO 2004 Annual International Convention, Stephen Sligar, Ph.D., Nanodisc co-founder/chief scientific officer and professor at the University of Illinois, will chair a panel discussion focused on recent advancements that are enabling more effective drug discovery efforts against membrane-bound protein targets. Dr. Sligar will be joined by speakers including James Wells of Sunesis Pharmaceuticals; Brian Hubbard of the Novartis Institutes for BioMedical Research; and Barry Springer of 3-Dimensional Pharmaceuticals. Compounds addressing membrane-bound targets constitute the majority of pharmaceutical products marketed today. However, these targets are notoriously difficult and expensive to study using traditional tools of drug discovery because they lose their natural characteristics when removed from their native environments, but cannot be easily manipulated and studied in those environments. To address this challenge, Dr. Sligar developed Nanodisc(TM) technology, a nano-scale, self-assembling disc that incorporates target molecules such as membrane proteins in such a way that their natural structural and functional characteristics are preserved and can be directly investigated. Nanodisc technology is an important, less expensive enabler for many molecular discovery approaches practiced by large life sciences companies, and represents an important advance in drug formulation and delivery. Dr. Sligar's panel, entitled "Membrane Proteins as Targets," will take place Monday, June 7, at 11:00 AM (pacific time) in room 2018 West at the Moscone Center in San Francisco. The BIO 2004 Annual International Convention is being held June 6-9. About Nanodisc Nanodisc Inc. commercializes Nanodisc(TM) technology to enable more effective and less expensive discovery of new drugs against membrane protein targets, the largest class of drug targets, and for drug delivery and drug formulation. Founded by Stephen Sligar, Ph.D., professor at the University of Illinois, Nanodisc has a worldwide, exclusive commercial license for all applications of Nanodisc technology with the U of I. For more information, please visit www.nanodiscinc.com . For further information please contact: Carin Canale of Atkins + Associates, +1-858-336-3027, for Nanodisc, Inc.
SOURCE Nanodisc, Inc.